Payment overview · 2025
General Payments
$1,054.97
39 reported records · 17 companies
Healthcare provider profile · identity verified
Sadia Khan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAGINAW, MI · NPI 1881633048
Verified facts
What the public records show
CMS Open Payments records show Sadia Khan, MD received $1,054.97 in general payments during 2025 across 39 reported records.
Axsome Therapeutics, Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lokelma by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $278.83 | 26.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.25 | 13.5% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $104.05 | 9.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $93.41 | 8.8% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $64.67 | 6.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $53.28 | 5.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.58 | 5.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $48.53 | 4.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.20 | 4.4% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $39.38 | 3.7% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $23.53 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.59 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.16 | 1.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.04 | 1.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.77 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.96 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.74 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,054.97 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $278.83 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $125.64 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $93.41 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.53 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $82.53 | 4 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $64.67 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.72 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $53.28 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $52.58 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $48.53 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $39.38 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 237 | 34 |
| Eliquis | Apixaban | 181 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 31 |
| Furosemide | Furosemide | 130 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 25 |
| Gabapentin | Gabapentin | 121 | 23 |
| Omeprazole | Omeprazole | 113 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 28 |
| Bumetanide | Bumetanide | 82 | 14 |
| Losartan Potassium | Losartan Potassium | 82 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 79 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 79 | 13 |
| Lisinopril | Lisinopril | 79 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 16 |
| Klor-Con M20 | Potassium Chloride | 74 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 13 |
| Levetiracetam | Levetiracetam | 65 | 13 |
| Sertraline Hcl | Sertraline Hcl | 64 | suppressed |
| Mirtazapine | Mirtazapine | 63 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 62 | 12 |
| Carvedilol | Carvedilol | 61 | 13 |
| Divalproex Sodium | Divalproex Sodium | 61 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Jantoven | Warfarin Sodium | 55 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Levemir | Insulin Detemir | 49 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 49 | 15 |
| Famotidine | Famotidine | 47 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Baclofen | Baclofen | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Metformin Hcl | Metformin Hcl | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | 13 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Novolog | Insulin Aspart | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 27 | suppressed |
| Pacerone | Amiodarone Hcl | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Klor-Con M10 | Potassium Chloride | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Paliperidone Er | Paliperidone | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,054.97 · 39 records | Axsome Therapeutics, Inc. | AFREZZA, AIRSUPRA, AUSTEDO XR, Auvelity, CAPLYTA, COLLAGENASE SANTYL, CREXONT, FANAPT, FUROSCIX, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, Ozempic, REXULTI, Rybelsus, TZIELD, Wegovy, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error